Breast Cancer Canada announces $500K in new grant funding
01 déc. 2022 13h58 HE
|
Breast Cancer Canada
SARNIA, Ontario, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Breast Cancer Canada today announced a call for proposals for their 2023 Precision Oncology Research Grants which will award $500,000 in new...
Insights on the Personalized Medicine Global Market to 2027 - Rising Number of Personalized Medicine Therapies Will Boost Growth
22 nov. 2022 07h39 HE
|
Research and Markets
Dublin, Nov. 22, 2022 (GLOBE NEWSWIRE) -- The "Personalized Medicine Market, Size, Share, Forecast 2023-2027, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis" report has been...
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 08h00 HE
|
Prelude Therapeutics, Inc.
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5...
Modifi Bio Receives $2.4 Million Award from National Cancer Institute to Advance Innovative Precision Oncology Platform
25 oct. 2022 08h00 HE
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in direct DNA modification developing novel cancer therapeutics, has been selected by the National Cancer Institute...
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
18 oct. 2022 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and...
Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
06 sept. 2022 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be...
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
06 sept. 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...
ITM Acquires a New Platform for the Development of Next-Generation Theranostics
18 août 2022 05h18 HE
|
ITM Isotope Technologies Munich SE
• Technology platform for PET tracers strengthens ITM’s radiodiagnostic portfolio • Additional assets potentially expand ITM’s pipeline of novel targeted radionuclide therapeutics Garching /...
Global Genomic Cancer Panel and Profiling Market Research Report 2022
27 juil. 2022 06h13 HE
|
Research and Markets
Dublin, July 27, 2022 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type With Screening Potential Market Size, Customized...
ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board
22 juil. 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, July 22, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board...